argenx SE (ARGX)’s Trend Up, Especially After Today’s Strong Session

March 14, 2018 - By Marry Poplack

The stock of argenx SE (NASDAQ:ARGX) is a huge mover today! The stock increased 4.99% or $4.04 during the last trading session, reaching $85. About 482,172 shares traded or 81.00% up from the average. argenx SE (NASDAQ:ARGX) has 0.00% since March 14, 2017 and is . It has underperformed by 16.70% the S&P500.
The move comes after 8 months positive chart setup for the $2.74 billion company. It was reported on Mar, 14 by We have $87.55 PT which if reached, will make NASDAQ:ARGX worth $82.17M more.

More notable recent argenx SE (NASDAQ:ARGX) news were published by: which released: “28 Stocks Moving In Tuesday’s Pre-Market Session” on January 30, 2018, also with their article: “25 Stocks Moving In Friday’s Pre-Market Session” published on December 15, 2017, published: “uniQure NV” on December 03, 2015. More interesting news about argenx SE (NASDAQ:ARGX) were released by: and their article: “28 Stocks Moving In Monday’s Pre-Market Session” published on January 29, 2018 as well as‘s news article titled: “No Shortage of Positive Retail Sector Surprises” with publication date: August 18, 2017.

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody therapies for the treatment of autoimmune diseases and cancer. The company has market cap of $2.74 billion. The companyÂ’s lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It currently has negative earnings. It is also developing ARGX-111 to treat solid tumors with MET amplification; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.